HealthDay - WEDNESDAY, July 16 (HealthDay News) -- Anti-rejection drugs given afterorgan transplants may be the reason why 15 percent to 20 percent ofindividuals who receive such transplants have a higher risk of developingcancer within the next decade.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.